header logo image


Page 241«..1020..240241242243..250260..»

Deep Longevity Adds Three Medical Organizations To Its Growing Longevity Network: Healthy Hire Healthy Retire, International Medical Clinics and Peak…

December 28th, 2020 12:52 pm

TipRanks

Semiconductors are one of the modern worlds essential industries, making possible so much of what we rely on or take for granted: internet access, high-speed computers with high-speed memory, even the thermostats that control our air conditioning there isnt much, tech-wise, that doesnt use semiconductor chips.With the end of 2020 in sight, its time for the annual ritual of evaluating the equities for the New Year. Wells Fargo analyst Aaron Rakers has cast his eye on the chip industry, tagging several companies as likely gainers next year.The analyst sees several factors combining to boost demand for chips in 2021, including cloud demand, new gaming consoles, and a market resolution to the future of the PC segment. Overall, however, Rakers expects that memory chips and 5G enabled chips will emerge as the drivers of the industry next year. The analyst expects that semiconductor companies, as a group, will see between 10% and 12% growth over the next 12 months.Thats an industry-wide average, however. According to Raker, some chip companies will show significantly higher growth, on the order of 30% to 40% in year ahead. We can look at those companies, along with the latest TipRanks data, to find out what makes these particular chip makers so compelling.Micron Technology (MU)Among the leading chip makers, Micron has staked out a position in the memory segment. The company has seen its market cap expand to $78 billion this year, as shares have appreciated 32% year-to-date. The surge comes on a product line heaving on computer data storage, DRAM, and flash storage.Look back at 2020, Micron has seen revenues increase each quarter, from $4.8 billion in Q1 to $5.4 billion in Q2 to $6.1 billion in Q3. Earnings came in at 87 cents per share, up from 71 cents in Q2 and 36 cents in Q1.The calendar third quarter was Microns 4QFY20, and the full fiscal year showed a decline due attributed to the COVID pandemic. Revenue came in at $21.44 billion, down 8.4% year-over-year, and operating cash flow fell to $8.31 billion from $13.19 billion in FY19. During this past quarter, Microns 1QFY21, the company announced the release of the worlds first 176-layer 3D NAND chip. The new chip promises higher density and faster performance in flash memory, and the architecture is described as a radical breakthrough. The layer count is 40% higher than competing chips.Looking ahead, Micron has updated its F1Q21 guidance, predicting total revenue of $5.7 billion to $5.75 billion. This is a 10% increase from the previous guidance.Wells Fargo's Aaron Rakers calls Micron his top semiconductor idea for 2021. He points out a deepening positive view on the memory, and in particular the DRAM industry. DRAM accounts for approximately two-thirds of Microns revenue and over 80% of the companys bottom-line profits. In addition, Rakers notes Microns technology execution 1Znm DRAM leadership; recently outlined 1nm ramp into 2021, as well as Microns move to 176-Layer 2nd -gen Replacement Gate 3D NAND to drive improved cost curve. We would also highlight Microns execution on graphics memory (e.g., GDDR6X), Multi-Chip Packages (MCPs), and High-Bandwidth Memory (e.g., HBME2) as positives.In line with these comments, Rakers rates Micron shares a Buy, along with a $100 price target. This figure suggests room for 41% growth in 2021. (To watch Rakers track record, click here)Micron has 24 recent reviews on record, breaking down to 19 Buys, 4 Holds, and 1 Sell, and giving the stock a Strong Buy from the analyst consensus. Shares are priced at $70.96, and recent appreciation has pushed them almost to the $74.30 average price target. But as Rakers outlook suggests, there may be more than just 4.5% upside available here. (See MU stock analysis on TipRanks)Advanced Micro Devices (AMD)With $6.5 billion in total sales last year, and a market cap of $110.7 billion, AMD is a giant company but it doesnt even crack the top five of the worlds largest chip makers. Still, AMD has a solid position in the industry, and its x86 processors provide stiff competition for market-leading Intel (INTC). AMD shares have shown solid growth this year, and are up 101% as 2020 comes to a close.The share growth rides on the back of steady revenue gains since the corona crisis peaked in Q1. AMDs Q3 top line came in at $2.8 billion, up 55% from the $1.8 billion recorded in the year-ago quarter and beating the forecast by 10%. Earnings, at 37 cents per share, were up 220% year-over-year. The company credited the growth to solid results in the PC, gaming, and data center product lines, and boasted that it was the fourth consecutive quarter with >25% yoy revenue growth.AMD announced last month a new product for the scientific research market, the Instinct MI100 accelerator. The new chip is billed as the worlds fasted HPC GPU, and the first such x86 server to exceed 10 teraflops performance.Covering AMD for Wells Fargo, Rakers wrote: We remain positive on AMDs competitive positioning for continued sustained gradual share gains in PCs We also believe AMDs deepening data center GPU strategy with new Instinct MI100 GPUs and the release of RoCM 4.0 software platform could become increasingly visible as we move through 2021. AMDs roadmap execution would remain an important focus 7nm+ Ryzen 4000-series, new RDNA Radeon Instinct data center GPUs (MI100 / MI120), and the 3 rd -gen 7nm+ EPYC Milan CPUsRakers stance supports his Buy rating, and his $120 price target implies a 30% one-year upside to the stock.The Moderate Buy analyst consensus view on AMD reflects some residual Wall Street caution. The stocks 20 recent reviews include 13 Buys, 6 Holds, and 1 Sell. AMD shares are selling for $91.64, and like Micron, their recent appreciation has closed the gap with the $94.71 average price target. (See AMD stock analysis on TipRanks)Western Digital Corporation (WDC)Closing out the Wells Fargo picks on this list is Western Digital, a designer and manufacturer of memory systems. The companys products include hard disk drives, solid state drives, data center platforms, embedded flash drives, and portable storage including memory cards and USB thumb drives. WDC has had a tough year in 2020, with shares down 19% year-to-date. Still, the stock has seen gains in November and December, on the heels of what was seen as a strong fiscal 1Q21 report.That earnings report showed $3.9 billion in revenue, which was down 3% year-over-year, but the EPS net loss, at 19 cents, was a tremendous yoy improvement from the 93-cent net loss in the year-ago quarter. The earnings improvement, which beat the forecast by 20%, was key for investors, and the stock is up 30% since the quarterly report. The company also generated a solid cash flow in the quarter, with cash from operations growing 111% sequentially.Wells Fargos Rakers acknowledges WDCs difficulties in 2020, but even so, he believes that this is a stock which is worth the risk.Western Digital has been our toughest constructive call of 2020 and while we believe calling a bottom in NAND Flash (mid/2H2021?) remains difficult and WDs execution in enterprise SSDs will remain choppy, our SOTP analysis leaves us to continue to believe that shares present a compelling risk / reward. We continue to believe that Western Digital can drive to a ~$7/sh.+ mid-cycle EPS story; however, we continue to think a key driver of this fundamental upside will not only be a recovery in the NAND Flash business, coupled with WDs ability to see improved execution in enterprise SSDs, but also a continued view that WDs HDD gross margin can return to a sustainable 30%+ level, Rakers opined.To this end, Rakers rates WDC a Buy along with a $65 price target. Should the target be met, investors could pocket gains of 29% over the next months Where does the rest of the Street side on this computer-storage maker? It appears mostly bullish, as TipRanks analytics demonstrate WDC as a Buy. Out of 11 analysts tracked in the last 3 months, 7 are bullish, while 4 remain sidelined. With a return potential of 9%, the stocks consensus target price stands at $54.44. (See WDC stock analysis on TipRanks)To find good ideas for tech stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Originally posted here:
Deep Longevity Adds Three Medical Organizations To Its Growing Longevity Network: Healthy Hire Healthy Retire, International Medical Clinics and Peak...

Read More...

Emerging Options for Treatment and Prevention of HIV Infection – Contagionlive.com

December 28th, 2020 12:52 pm

Moderator

Joseph Eron, MDProfessor of Medicine, Division of Infectious DiseasesUniversity of North Carolina School of MedicineChapel Hill, NC

Panelists

Allison L. Agwu, MD, ScMAssociate Professor of Pediatric and Adult Infectious DiseasesJohns Hopkins University School of MedicineBaltimore, MD

Ian Frank, MDProfessor of MedicineUniversity of Pennsylvania Perelman School of MedicinePhiladelphia, PA

Colleen F. Kelley, MD, MPHAssociate Professor of Medicine, Division of Infectious DiseasesEmory University School of MedicineAtlanta, GA

Julia Marcus, PhD, MPHInfectious Disease EpidemiologistAssociate Professor, Department of Population MedicineHarvard Medical School and Harvard Pilgrim Health Care InstituteBoston, MA

New antiretroviral drugs with unique mechanisms of action and delivery provide promising options for treatment and pre-exposure prophylaxis (PrEP) of HIV infection and may improve adherence in certain subgroups of individuals. However, the development of an effective vaccine remains elusive, according to experts who participated in a recent Contagion Peer Exchange panel.

Emerging Treatment Options for HIV

Fostemsavir (formerly BMS-663068/GSK3684934), a prodrug whose active metabolite (temsavir) is a first-in-class attachment inhibitor that binds directly to the viral envelope glycoprotein 120 near the CD4+ binding site,1 was approved by the FDA on July 2, 2020, for adults living with HIV who have tried multiple HIV medications and whose infection cannot be treated with other therapies because of resistance, intolerance, or safety reasons.2 This approval was based largely on results from a phase 3 trial, which showed a virologic response (HIV-1 RNA <40 copies/mL) at week 48 in 54% of patients with heavily pretreated, multidrug-resistant HIV infection who received fostemsavir plus optimized background therapy.3 Session moderator Joseph Eron, MD, said that its oral dosing is advantageous over ibalizumab, which is dosed intravenously, although he said that fostemsavir will probably be limited for patients with few or no treatment options.

Allison Agwu, MD, added that long-acting injectable and oral agents, capsid inhibitors, and monoclonal antibodies are also being studied in the HIV space, as are alternative delivery approaches, such as subcutaneous injections, pumps, implants, and patches. However, she pointed out that access to and the cost of these novel options will be key issues moving forward, particularly when currently available oral agents are highly effective for suppressing HIV viral load in the majority of cases.

The discussions well have to have on how and who and where are going to be very important, said Agwu. It doesnt mean we shouldnt have those discussions because for the people who are living with HIV, these are maybe life-saving, game-changing remedies for them.

Long-Acting Injectable Therapies to Treat HIV

The panelists discussed potential uses and challenges with the long-acting injectable therapy containing cabotegravir (an HIV-1 integrase strand-transfer inhibitor) and rilpivirine (a non-nucleoside reverse-transcriptase inhibitor), which is injected in 2-mL doses in the gluteus medius every 4 weeks for the maintenance of virologic suppression in patients who are initiating or transitioning therapy. Although the FDA declined to approve the combination in December 2019 due to concerns related to chemistry manufacturing and controls, the drug manufacturer (ViiV Healthcare) stated that no related safety issues have been reported and the safety profile of the products has not changed. ViiV Healthcare submitted another new drug application that was accepted in April 2020.

Colleen Kelley, MD, said that a benefit of long-acting injectable dosing is that it may help reduce the internalized stigma for many individuals living with HIV who take a daily oral medication. Its a constant reminder when you have that pill bottle on your bathroom stand that says, I am HIV positive, she noted.

However, the panelists pointed out potential drawbacks with long-acting injectables, such as the risk for drug resistance in patients who miss injections and the possible need to modify the clinic set-up to ensure availability of nursing staff when patients are receiving injections.

Although there may be some adherence problems that get solved by the injections, I think that there are other adherence risks that get created, said Ian Frank, MD. Itll be more incumbent upon us as providers to ensure that our patients are coming in at the appropriate frequency, and we may need to modify our practices.

Long-Acting Injectables as Pre-Exposure Prophylaxis

Long-acting injectable therapy with cabotegravir may provide a discreet option for PrEP that does not require daily dosing, according to a recent interim analysis of the phase 2b/3 HPTN 083 trial (NCT02720094).4 The interim results from the trial showed that cabotegravir injection every 8 weeks was superior to daily oral emtricitabine/tenofovir (Truvada) for preventing HIV acquisition in cisgender men who have sex with men and transgender women who have sex with men.4

To have population-level effectiveness, long-acting injectable PrEP needs to cater to a population of individuals who are eligible for and interested in receiving it but are not interested in daily oral PrEP, according to Julia Marcus, PhD. If the only people who are interested in long-acting PrEP are people who are already taking daily PrEPits not going to have any population-level effectiveness, she said.

Marcus added that identifying individual barriers to receiving oral PrEP is important to assess whether long-acting injectable PrEP is appropriate for them, noting that it would be more likely to benefit an individual who forgets to take daily medications than one who has difficulty with coming into the clinic.

If their [issue is] that they dont want to be coming into the clinic every 3 months, long-acting injectables may not help them, she said. They may have to come in even more.

Other individuals who may be good candidates for long-acting injectable PrEP include those for whom having oral medication may put them at risk for bodily or emotional harm, such as people in unequal power relationships, commercial sex work, or homeless living situations, said Eron and Marcus. Individuals who use injectable drugs or are on methadone maintenance may also be good candidates for PrEP if they come in frequently for syringe changes, said Marcus.

Agwu added that long-acting injectable PrEP could also expand the options in the armamentarium for a given patient at different times of their life.

If a patient has to go abroad for 2 months, maybe thats the time to get your shot, she said. You dont have to worry about taking your pills to Morocco.

She said that further work is needed to optimize system and administration issues and improve practices for delivering long-acting injectable therapy in the clinic. Eron concluded that further research to ensure the efficacy and demedicalization of PrEP is important to improve uptake, as the perception that PrEP care is more intensive than HIV care continues to persist among individuals who are eligible for PrEP.

Preventative and Therapeutic HIV Vaccines

Although the phase 2b/3 HVTN702 trial (NCT02968849), which studied the RV144 Thai vaccine regimen for the prevention of HIV infection in South Africa, was recently discontinued because of a lack of efficacy, Kelley said that this outcome does not mark the end of the journey for finding an effective vaccine, which will be the key to ending the HIV epidemic.

Theres still more work to be done and no reason to lose hope, she said. Were thinking about monoclonal antibodies and long-acting antiretrovirals in place of a traditional vaccine.

Kelley said that researchers are getting closer to identifying what the immune system needs to do to protect itself from HIV infection. If these neutralizing antibodies are the key, how do we make our human immune system create those neutralizing antibodies? .Thats been extremely difficult to do, she said. We can make the antibodies outside the person, but we cant make the person produce the antibodies. This is the biggest barrier right now.

Frank added that therapeutic vaccines are also being investigated as a strategy for curing HIV, with cure defined in the context of doing something other than requiring people to take regular antiretroviral therapy to control the virus replication. Specifically, the goal of a therapeutic vaccine is to improve the individuals immune response against the infection to enable the withdrawal of antiretroviral therapy and promote an improved immune response to control virus replication, said Frank. He concluded that although therapy and prevention continue to improve, the absence of an effective vaccine and a cure are the real vacuum in HIV prevention and treatment, respectively.

Advice for Physicians Treating Patients with HIV

At the conclusion of the exchange, the panelists discussed tips for physicians in the screening, diagnosis, and treatment of patients living with HIV. Agwu stressed the importance of asking patients about risk factors for HIV, including sexual activity, and testing and offering PrEP for patients at high risk. Kelley added that in addition to routine discussions about sexual health, maintaining consistency in the treatment of each patient and identifying other issues that are common to those living with HIV, such as other sexually transmitted infections, is important.

Marcus added that discussing sexual health in an open-ended, nonjudgmental, patient-centered way is important for optimal communication with patients and that communicating the U = U (undetectable = untransmissible) message can be transformative for them.

Frank concluded that although undetectable viral load is often the primary focus of antiretroviral therapy, providers should also consider additional factors, such as comorbid conditions, when optimizing HIV therapy and managing overall care for patients.

Its important that we remind our patients that they may have other medical conditions, or they may develop other medical conditions, and those medical conditions may pose as great a risk, if not a bigger risk, than their HIV disease, said Frank. I have many patients with uncontrolled hypertension and uncontrolled diabetes and lipids that are high. I tell them that theyre going to die of a heart attack or a stroke or be on dialysis long before they ever get a complication of their HIV. Dying of a heart attack with an undetectable viral load isnt my goal of their treatment. Its not just about their HIV.

References

1. Langley DR, Kimura SR, Sivaprakasam P, et al. Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action. Proteins. 2015; 83(2):331-350. doi:10.1002/prot.24726

2. FDA approves new HIV treatment for patients with limited treatment options. Press release. FDA. July 2, 2020. Accessed October 13, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-treatment-patients-limited-treatment-options.

3. Kozal M, Aberg J, Pialoux G, et al; BRIGHTE Trial Team. Fostemsavir in adults with multidrug-resistant HIV-1 infection. N Engl J Med. 2020;382(13):1232-1243. doi:10.1056/NEJMoa1902493

4. Long-acting injectable form of HIV prevention outperforms daily pill in NIH study. News release. National Institutes of Health. July 7, 2020. Accessed October 13, 2020. https://www.nih.gov/news-events/news-releases/long-acting-injectable-form-hiv-prevention-outperforms-daily-pill-nih-study

Read this article:
Emerging Options for Treatment and Prevention of HIV Infection - Contagionlive.com

Read More...

Prairie People: New hires and promotions – Grand Forks Herald

December 28th, 2020 12:52 pm

Dale Carnegie of North Dakota and Northwest Minnesota has new ownership

FARGO, N.D. Bethany Berkeley is now the CEO and co-owner of Dale Carnegie of North Dakota and Northwest Minnesota. She partners with Katie Munion, who is the chief transformation officer and co-owner.

Both women begin this journey with strategic focus, a wealth of experience and grateful hearts. Theyve been in the business and know the industry. Prior to ownership, Berkeley was the managing partner and president, and Munion was the vice president of training and quality.

They are excited to continue offering the core Dale Carnegie courses and in-house customized training solutions with a specialized focus on communication and interpersonal skills, presence and storytelling, sales and customer service excellence, leadership training for new and aspiring managers and experienced managers. All solutions are offered in versatile formats: in-person (socially distanced at minimum capacity), live-online, or blended.

They represent clients primarily in the manufacturing, distribution, engineering, construction, government, agriculture, technology, finance, and professional service industries. They also have a new space to collaborate and facilitate training solutions -- the Railyard at 1630 1st Ave. N. in Fargo.

Enclave welcomes two new team members

FARGO, N.D. Ashley Kossan has joined Enclave as accounts payable & receivable specialist.

A graduate of North Dakota State University, Kossan brings experience as an accountant, mortgage loan officer and royalties analyst. Originally from Minot, N.D., she previously served as an accountant at Legendary Capital.

Enclave also has hired Travis Golobich as assistant project manager.

A native of Coon Rapids, Minn., and a graduate of North Dakota State University, Golobich joins Enclave with more than seven years of experience in project management. Previously, he served as project manager at Moorhead Electric.

In his role at Enclave, Golobich will assist in collaborating with the construction and design teams, sub- contractors, and clients to ensure timely project delivery within budget.

Essentia Health hires new health provider

FARGO, N.D. Essentia Health welcomes Dr. Olayinka David Ajayi

Dr. Olayinka David Ajayi has joined the Essentia Health team in Fargo, where he specializes in hyperbaric medicine. Hyperbaric oxygen therapy is a noninvasive, painless procedure that uses 100% oxygen in a pressurized chamber to improve the bodys natural healing process, treat carbon monoxide poisoning and other FDA/UHMS approved medical conditions.

Dr. Ajayi received his medical education at the University of Ibadan College of Medicine, Nigeria. He earned his masters degree in public health and completed a residency in public medicine at Emory University Public Health, Atlanta, Ga.

His fellowship in undersea and hyperbaric medicine was completed at Hennepin Healthcare in Minneapolis, Minn. Dr. Ajayi is board certified by the American Board of Medical Specialties in public health and general preventative medicine.

Alerus hires new senior business advisor and senior financial guide

FARGO, N.D. Alerus has welcomed Brad Loween as senior business advisor. In this role, Loween serves as the trusted point of contact for business clients, delivering comprehensive financial advice to help them achieve their financial wellness goals.

Loween works closely with experts across Alerus to serve business clients holistic financial needs and ensure access to the companys full suite of diversified services.

Loween has nearly a decade of experience in the financial industry, with expertise in wealth management and business banking. He holds a bachelors degree in biology from Montana State University and served 21 years in the North Dakota National Guard, including deployments to Afghanistan and Kosovo.

He is a volunteer for the Fargo Moorhead West Fargo Chamber of Commerces Military Affairs committee and the Department of Defenses Employer Support of the Guard and Reserve program. He also serves as a board member for Rebuilding Together of Fargo-Moorhead.

Alerus also has welcomed Isaac Bumgardner as senior financial guide. In this role, Bumgardner is responsible for assisting clients in identifying their specific financial needs and providing comprehensive advice to help them achieve their financial wellness goals.

He works closely with experts across Alerus to ensure each client has access to the companys full suite of diversified services.

Both of the new hires are based at Alerus office at 51 Broadway in Fargo.

Send your promotions and new hire information to aweeks@prairiebusinessmagazine.com.

Read the rest here:
Prairie People: New hires and promotions - Grand Forks Herald

Read More...

Antibody study aims to protect those exposed to coronavirus from illness – The Jerusalem Post

December 28th, 2020 12:52 pm

Two new clinical trials in the UK are examining whether administering an antibody combination after someone has already been exposed to the novel coronavirus could protect them from developing COVID-19, the disease caused by the virus.

The University College London Hospitals (UCLH) NHS Trust announced on Friday that it is running the trials at a new vaccine research center.

Both trials are examining AZD7442, a long-acting antibody (LAAB) combination developed by AstraZeneca.

The first study, called STORM CHASER, is examining whether the antibody can provide immediate and long-term protection to people recently exposed to the SARS-CoV-2 virus.

We know that this antibody combination can neutralize the virus, so we hope to find that giving this treatment via injection can lead to immediate protection against the development of COVID-19 in people who have been exposed when it would be too late to offer a vaccine, said study leader UCLH virologist Dr. Catherine Houlihan in a press release from the hospital.

STORM CHASER had recruited 10 people as of Friday. Key participants will include healthcare workers, students in group housing, patients exposed to anyone with the virus, residents of long-term care facilities and those in industrial or military settings.

THE SECOND study, called PROVENT, is examining whether people who may not respond to the vaccine, including immuno-compromised people, or at-risk groups, such as the elderly or those with preexisting conditions, may be helped by AZD7442, even prior to exposure.

cnxps.cmd.push(function () { cnxps({ playerId: '36af7c51-0caf-4741-9824-2c941fc6c17b' }).render('4c4d856e0e6f4e3d808bbc1715e132f6'); });

We will be recruiting people who are older or in long-term care, and who have conditions such as cancer and HIV, which may affect the ability of their immune system to respond to a vaccine," said UCLH infectious diseases consultant Dr. Nicky Longley, the head of the study. "We want to reassure anyone for whom a vaccine may not work that we can offer an alternative, which is just as protective.

Both UCLH studies will examine whether AZD7442 reduces the risk of developing COVID-19 and/or reduces the severity of the infection compared to a placebo.

Trial participants will be able to safely leave the study in order to get licensed vaccines if it is deemed medically beneficial, according to UCLH.

Antibodies are produced by the body to help fight infections. Monoclonal antibodies are artificially produced in laboratories for possible medical treatments in patients already infected with the virus and could provide protection before exposure as well.

While vaccines train the body over a matter of weeks to produce its own antibodies, antibody injections skip that step, aiming to provide immediate protection against viruses.

AZD7442 is a combination of two LAABs derived from recovering patients that were discovered by Vanderbilt University Medical Center and then licensed to AstraZeneca, according to the company, which then optimized the LAABs with half-life extension in order to increase the durability of the therapy for six to 12 months. The combination is also designed to reduce the risk of resistance developed by the virus.

In pre-clinical experiments published in Nature, the LAABs in AZD7442 were shown to block the novel coronavirus from binding with host cells, protecting against infection.

UCLH'S NEW Vaccine Research Center, which opened in December, is operating under the patronage of the National Institute of Health Research (NIHR) UCLH Biomedical Research Center and the UCLH Research Directorate, and represents an extension of the NIHR UCLH Clinical Research Facility led by Prof. Vincenzo Libri.

Libri is also a principal investigator on the Oxford/AstraZeneca vaccine trial and provides oversight of all COVID-19 vaccine/preventative treatment trials.

Mene Pangalos, AstraZeneca's executive vice president of BioPharmaceuticals Research & Development, stated in the UCLH release that AZD7442 has the potential to be an important preventative and therapeutic medicine against COVID-19, focusing on the most vulnerable patients."

"The STORM CHASER trial in particular is a unique approach, with enrollment initiated on site following the identification of a confirmed case to halt the spread of COVID-19 in the facility or community," Pangalos said. "We offer our appreciation and gratitude to everyone involved in these trials from the scientists, researchers and clinicians, to the trial participants and study sites as we all work together to help end this pandemic.

Antibody treatments have been evaluated since nearly the beginning of the pandemic.

In May, the Israel Institute for Biological Research (IIBR) completed a groundbreaking scientific development, identifying an antibody that neutralizes the coronavirus.

Maayan Jaffe-Hoffman, Anna Ahronheim and Idan Zonshine contributed to this report.

Here is the original post:
Antibody study aims to protect those exposed to coronavirus from illness - The Jerusalem Post

Read More...

2-year degrees that go on to the most meaningful jobs – Gwinnettdailypost.com

December 28th, 2020 12:52 pm

A third of a lifetime is spent working, making a meaningful career a critical life decision. Having a consequential career is not about monetary gain for many hard-working Americans. On the contrary, it is about making a marked difference in the world. Take, for example, teachers, who shape the minds of future generations. While the entry-level annual salary for teaching is slim compared to other careers, it doesn't stop the thousands who pursue a career in education because they find great purpose in their profession.

Studies also show that those who love their work live longer, which is a priceless consideration when choosing a profession. Balancing out working a meaningful job and making the median full-time wage (around $50,000) can be challenging, but it's possible to live the dream and make a decent living at the same time. Stacker compiled a list of two-year degrees using 2020 data from Payscale on the most meaningful employment. Jobs are ranked by degrees whose graduates report having a high meaning job, with ties broken by highest mid-career pay.

Many of the degree programs and jobs listed are in the health care field, ranging from medical secretarial science to alcohol and drug studies. While some find meaning in providing administrative support, others find daily joy in performing diagnostic tests. All of the jobs listed assist the general public in one way or another, requiring an altruistic attitude.

Money certainly plays a small role in job satisfaction, with seven of the top 10 most meaningful jobs earning mid-career pay above $60,000 per year. Helping others won out over money however, as the top job on the list saw its professionals earn less than $50,000 by the mid-point of their careers.

Continue reading to find out the two-year degrees that go on to the most meaningful jobs.

You may also like: Highest-paying state for 50 different jobs

Read this article:
2-year degrees that go on to the most meaningful jobs - Gwinnettdailypost.com

Read More...

Why Data is the Real Value Behind VR – MarketScale

December 28th, 2020 12:52 pm

On Spatial Perspectives, host Dan Cui will have a one-on-one dialog with innovators and thought leaders in the growing Spatial Reality, or Spatial Computing, market. Cui will invite guests who can discuss the real world use cases of the technology and how it could benefit mankind while exploring any drawbacks and how they might be mitigated.

It is an undeniable fact that data affects our everyday lives. While data gets a bad rap in the news when associated with data breaches or privacy concerns, the collecting and analyzing of data can change lives. Stan Karpenko, Co-Founder & CTO at GiveVision knows this first hand. Dan Cui, Host, Spatial Perspectives, sat down with Karpenko to learn more about the true value of data.

GiveVisions goal is to make the lives of visually impaired people better with the help of their products and services. One such asset they provide to those who are visually impaired is a services product thats attached to their glasses that will allow the clinicians to have the ability to actually monitor their patient and provide new treatment regimes for that patient based on what they see happening on a daily basis.

When it comes to data, Karpenko feels it is a vital element of developing products that can help people. I think the data becomes the key part. I think the hardware becomes irrelevant over time, it will become a commodity. The real insights and the real values in the data, Karpenko said. He posed important questions like, can we effectively collect the healthcare data about the patient over a long period of time to make clinical decisions? Can we arrive at a point in time where we dont need the patient to call the doctor when they can feel the symptoms? Can we pick up the symptoms before they can feel them? So the entire sort of changing the career pathway is really what we see as the biggest opportunity facing the AR and VR world. I think, in reality, theres an enormous opportunity for AR and VR companies to develop products that will, just the same as smartwatch, become just a vehicle to collect healthcare data for the benefit of the patient, Karpenko explained.

He believes that those devices will be used for entertainment, or in our case as an enabler for them to do things. But as a byproduct of that, they will be able to watch for patients and inform the doctor when they need to see the patient before its too late. So thinking about preventative medicine if you like, Karpenko said.

For more insight into how data is a key element of progress, listen in to this weeks episode of Spatial Perspectives.

Follow us on social media for the latest updates in B2B!Twitter @TechMKSLFacebook facebook.com/marketscaleLinkedIn linkedin.com/company/marketscale

More:
Why Data is the Real Value Behind VR - MarketScale

Read More...

MK warns of spiritual side effects as vaccination drive continues on Shabbat – The Times of Israel

December 28th, 2020 12:52 pm

Ignoring rabbis objections, and prompting fury from religious politicians, Israel vaccinated thousands of citizens on Shabbat.

The Health Ministry views all-week-long vaccination as key to achieving quick coronavirus protection part of a plan, which also involves 24-hour clinics, to vaccinate more than 150,000 a day.

This past Saturday, the first of the vaccination drive, all four healthcare providers carried on giving shots to the 60-plus public, albeit at significantly reduced capacity, they told The Times of Israel.

Get The Times of Israel's Daily Edition by email and never miss our top storiesFree Sign Up

MK Uri Maklev of United Torah Judaism slammed the Health Ministry for encouraging it. How will there be a blessing for the work of their hands, when they harm Shabbat and the [religious] public in such a serious manner? he asked rhetorically in a Haredi newspaper on Sunday.

A woman receives a coronavirus vaccine at a clinic run by the Meuchedet healthcare provider. (courtesy of Meuchedet)

The politician claimed that Health Minister Yuli Edelstein had promised him that there would not be Shabbat vaccinations, and attacked the justification given to administer them.

Edelstein said it was done so that the country can quickly deliver COVID-19 protection, and invoked the Jewish legal principle of saving a life, or pikuah nefesh, which trumps nearly all other religious requirements, including Shabbat. The coronavirus endangers all of us, the vaccines will save all of us, he said.

Hospital workers in protective gear are seen in the coronavirus ward at Ziv Medical Center in the northern city of Safed on October 7, 2020. (David Cohen/Flash90)

But many Orthodox Jews say that pikuah nefeshdoes not normally extend to preventative medicine. They put everything in the category of pikuah nefesh, Maklev said of Health Ministry leaders. We have seen in the past that many of their instructions did not stand up to scrutiny.

There is no prohibition on administering or receiving a vaccine on Shabbat, according to most rabbis, but they say clinics should stay shut because their operation involves other actions considered to desecrate the holy day of rest, like logging patient information on computers and operating other electrical items that are needed. They also express concern that people are made to break the religious rule against driving on Shabbat to make their appointments.

The chief rabbis have refused to back operation of vaccine centers on Shabbat for now. Currently, there is no permission to violate Shabbat for the sake of vaccination, Ashkenazi Chief Rabbi David Lau said on Thursday, according to Orthodox media.

Israels Ashkenazi Chief Rabbi David Lau at the Western Wall, in the Old City of Jerusalem, July 21, 2019. (Noam Revkin Fenton/Flash90)

He stressed that he supports vaccination, but argued that so long as clinics are not operating during every hour of every other day, working on Shabbat is not justified. For now, they should ramp up capacity without working Saturdays, he argued.

If and when clinics are vaccinating 24/6, it will be possible to consider also vaccinations on Shabbat, Lau said.

Even if the chief rabbinate eventually gives its blessing to Shabbat shots, there are indications that some influential ultra-Orthodox rabbis will remain steadfast in their objection to them.

The massively influential ultra-Orthodox halachic authority Rabbi Asher Weiss wrote that the situation is not urgent enough to consider vaccination an act of pikuah nefesh.

Rabbi Asher Weiss. (Gershon Ellinson/Flash90)

He was responding to questions from the UK and the US, so it is possible that he will issue another ruling regarding Israel. If he does not, Shabbat vaccination, even if part of a 24/7 campaign, is likely to remain taboo for a large part of the Israeli Haredi community, including politicians from Maklevs party, who revere the rabbi.

The one proviso in Weisss position was for people in high-risk categories, or who risk infecting people who are high-risk. If they have Shabbat appointments that cannot be moved without incurring delays, in some circumstances, he would allow them to be treated and even driven to the vaccination station in certain cases, though by a non-Jewish person, and not by a Jewish person who, in his estimation, is supposed to be observing Shabbat.

Religious objections are not stopping healthcare providers. A spokeswoman for Maccabi Healthcare Services told The Times of Israel that her nurses vaccinated 7,000 people on Shabbat, some of whom had appointments for next month and were offered to vaccinate earlier if they took Saturday appointments. Opposition from rabbis would not stop them during future weekends, she said.

Meuhedet gave 1,500 injections, mostly in Netanya and Tel Aviv. Leumit gave 2,000, mostly in central Israel. Clalit only operated in the Arab Jerusalem neighborhood of Sheikh Jarrah.

Weiss and Lau both hail from the ultra-Orthodox community. But while religious Zionist rabbis are often thought to take more lenient approaches than their Haredi counterparts, when it comes to this issue, they have not done so.

Rabbi Shlomo Aviner (Yossi Zamir/Flash90)

If they arent working at night, its serious but not urgent, leading religious Zionist Rabbi Shlomo Aviner told The Times of Israel on Sunday, saying no to Shabbat vaccinations. Like Lau, he said that if Israel were providing vaccinations 24/6, the answer might be different.

Aviner, one of the stricter rabbis of religious Zionism, said: The vaccine itself does not involve Shabbat desecration, but the actions around it are, giving examples of logging patient data on computers.

His observation that the injection itself does not transgress Shabbat reflects the laws as they are found in the book, Shemirat Shabbat Kehilchatah, widely viewed as the authoritative Orthodox laymans guide for Sabbath observance.

The Hebrew text from the religious guide, Shemirat Shabbat Kehilchatah, which says that there is no Torah prohibition on taking a regular vaccine on Shabbat. (Zak Jeffay)

Rabbi David Stav, chairman of the moderate Orthodox rabbinic alliance Tzohar, also said he cannot justify Shabbat vaccinations for now, apart from very high risk populations, but added that he hopes this will change.

I urge the government to decide how important it is to keep centers open, and if they are open 24/6, Im almost positive that rabbis would allow vaccination on the seventh day as well.

More:
MK warns of spiritual side effects as vaccination drive continues on Shabbat - The Times of Israel

Read More...

Love Island’s Dr Alex George opens up about the hardest year of his life – Devon Live

December 28th, 2020 12:52 pm

Former Exeter University student and Love Island contestant Dr Alex George has opened up about dealing with grief and working though the coronavirus pandemic after the sudden death of his younger brother.

The A&E doctor, from Carmarthenshire, bravely spoke out about coming to terms with his loss in a year which has also seen him work 18-hour days for weeks on end balancing his role as a frontline medic with his role as a public health figure.

On July 24, Alex - who studied medicine at the University of Exeter - shared news of his 19-year-old brother's death in a heartbreaking post on social media.

Llyr, a talented student who was about to start medical school, took his own life.

Now Alex has spoken about his determination to help others with their mental and physical health to try and prevent other families from going through the pain that his family have endured over the last six months.

You can stay up to date on the top news near you with DevonLive's FREE newsletters enter your email address at the top of the page.

Speaking to WalesOnline the 30-year-old said: "Its an up and down journey. I think what is interesting is that my life feels a bit like before and after there is this big line of separation.

"My memories feel very distant but I think thats part of a trauma like this. Grief is an ongoing thing.

"Especially with the pandemic, work, and obviously Im living alone, its not helping unfortunately. Saying youre allowed to bubble with other people is one thing but the reality is you dont see people very much.

"But Ive been able to see my family and I have a really good set of friends so we are getting through it. Its just about taking each day as it comes and trying to do something positive. I bury myself in my work quite a lot which is both a good and bad thing but it does help me in scenarios with things like this.

"[Christmas] will be tough, all of the firsts will be hard and Christmas will be really tough but well get through it. We dont have any other options. I would never wish this on anyone else you just have to accept its happened to you and do what you can with your life."

In the weeks and months after his brother's death Alex has not shied away from talking about a situation that to many people is simply unimaginable.

Speaking to Lorraine Kelly in September the former reality star described how he had been in a restaurant with friends in London when his dad phoned him with the news. In the emotional interview he went on to talk about how he and his brother Elliott had to drive together back to Wales sitting in silence, crying, and shouting in anguish during the unthinkable five-hour journey.

He has also spoken about the trolling he had endured and shared one message that read: "Your brother is dead, get off social media" to which Alex responded: "Imagine being this person. Im holding by a thread and you get people like this."

Despite everything, what Alex is determined to do is pay tribute to a younger brother who he describes as a "mini me" a conscientious, empathetic, and confident teenager and talented footballer who would have doubtlessmade a "very good doctor".

Alex said: " It is hard. At the moment [Llyr's] name is associated with a certain thing and suicide and its very very hard to separate that but we do do our best. Ive got pictures and stuff of him and we do try and laugh about certain things. I saw a meme and I just thought: 'Hed laugh at that' you have got to think about those things.

"I think its important to be open. I would never want to shy away from whats happened. With suicide theres no shame in it. Its the same as if someone has a heart attack its a very sad, preventable cause of death of course but its not something I would ever be ashamed of. Its happened we have to try and do something positive.

"Its hard enough to deal with it anyway but quite frankly in the public eye it's tough but also the amount of support Ive had is unbelievable. There is no doubt, really, people have been so kind I think social media gets a bad rep sometimes, even the media in general, but people have been very kind and supportive and thats helped me a lot."

It's not just online that Alex has received support however. When his mother Jane started knitting to help keep herself busy dozens of people from the Carmarthen community put in orders to buy her products, which will raise money for mental health charities. Then there are those who also volunteered to help, creating an "army of knitters" for the Welsh bank worker.

Alex added: "She started knitting to try and distract herself. She had that feeling of guilt you inevitably get in that scenario, especially as a mother or father. So she sat there and said: 'Ill knit to distract myself' and thought: 'Well, Ill try and sell some of this stuff'.

"Someone actually bought a pair of her gloves and then she thought 'People might buy this' and all of a sudden the orders started coming in.

"My dad is retired, my mum is still working in a bank but obviously is off on long-term leave and its really, really tough. If you sit still too long its not good for you. You need to keep busy its not good for you to not to be active mentally."

When it comes to keeping busy it would be difficult to overemphasise how hard Dr Alex has worked this year. Working in the A&E department of University Hospital Lewisham in south London he and his team have seen first-hand how hard the area has been hit by Covid-19. That's at the same time as the content Alex has been sharing with his combined two million followers on Instagram and YouTube talking about everything from vaccines to health and wellbeing advice.

In his podcast series, the Waiting Room, he and emergency medical consultant Dr Anna Colclough describe facing huge amounts of patients coming in and needing to be intubated both young and old. You can find more about that here.

Video Unavailable

Click to playTap to play

Play now

Alex, speaking in mid-December, said: "Lewisham was hit so hard and so early that we kind of realised that it was coming. The speed in which it happened and how unwell patients were coming in, it was obvious we had a big problem so there was a real realisation that something terrible was happening.

"Lewisham and south London has been very, very hard-hit. In fact we are going through a very difficult wave at the moment, we are really busy at the moment the hospital is full with a lot of Covid patients.

"Its been tough, its been really tough, but the sense of teamwork we have, weve pulled together, the camaraderie, we really are a team. Weve looked out for each other and supported each other so in many ways its been a reminder that there are other things in the world.

"Its something you look back on now and you think: 'At least I felt I was a part of it, at least I could do something positive'. I do feel that throughout the pandemic in hospital and through using my platform that I have helped people. And I do think I get some comfort from that.

"I love my job, its my passion, and I would feel very lost without it."

Talking about managing the second wave of the pandemic this winter, Alex added: " I gave so much in round one, Ive got to try and preserve a bit of energy the second time. It nearly killed me that first round.

"There were 18-hour days almost I did 22 weeks and I didnt take a single day off. I wasn't necessarily in A&E every day, I was going into A&E four or five days but Id be doing YouTube videos. PHE [Public Health England] were expecting us to do a huge amount of advisory stuff, most people would listen to doctors and not presenters, so the amount of responsibility to create this content was huge. Im a little bit burnt out. "

Despite everything this year has brought Alex is determined to remain positive for the new year ahead. Next year he hopes to transition into GP work as well as his A&E role a move into the preventative medicine he has become passionate about, especially giving advice around mental and physical health.

In May 2021 he will also celebrate the release of his first book Live Well Every Day a book addressing the modern health challenges we face and how little changes to our routines can make a big difference. According to Alex using the principles and advice in his book has helped him deal with his hardest days, from his time as a medical student to the monumental challenges he is now facing.

Explaining the thinking behind his book, he said: "The idea of the book came many years ago when I was at medical school.

"I ended up being on placement somewhere that I was a bit isolated and started feeling not myself. I stopped exercising, I started eating badly, I was sleeping quite badly, I wasnt really seeing friends. I wasnt doing the things that I knew were right for me and my mental health and my own happiness as well.

"I made changes, little changes I started going outside for a walk every day, I started exercising every day, I planned my own meals, healthy meals, I planned bedtimes, I had time off my phone, doing all those good things. I became quite isolated so I made a plan to call someone every night someone different, a friend, a family member, every night and chat with them.

"I found those changes, an accumulation of those changes, meant that I just felt so much happier and healthier and I think thats the premise of this book giving people those tools they can use to make small changes to their own lives that ultimately that will make changes to not just their mental health but physical health too.

"Most of the book I wrote through the pandemic actually. I felt quite inspired and quite driven to write it with everything that happened with my brother.

"The book isnt written for him in that sense but I do feel it was a huge motivating factor. I couldnt help him but maybe this book will help other people and hopefully can protect people from ending up in that scenario.

"He was very proud of it he was really excited about the book. I had written a bit of it and we had actually had the publishing contract and agreement and he was so excited the book was coming to life."

You can pre-order Live Well Every Day from retailers including Amazon, Waterstones, and WHSmith.

Samaritans (116 123) operates a 24-hour service available every day of the year. If you prefer to write down how youre feeling, or if youre worried about being overheard on the phone, you can email Samaritans at jo@samaritans.org.

View post:
Love Island's Dr Alex George opens up about the hardest year of his life - Devon Live

Read More...

Israel Paying Economic Price for 4th Election in 2 Years – The Media Line

December 28th, 2020 12:52 pm

Economic uncertainty and instability are real cost of Israels elections

Elections cost money. And Israels upcoming election, the fourth in two years, will cost much more than previous ones.

The financial burden of the election on state coffers is compounded by the fact that the government has not passed national budgets for 2020 and 2021.

The cost of holding Israels upcoming election, scheduled for March 23, 2021, is estimated at close to 500 million NIS ($155.4 million). This is at least 20% higher than the last elections in March 2020 and higher by as much as 40% than the first election in the last two years that took place in April 2019.

There is a price for everything, and a democracy requires spending money, Giora Pordes, spokesman for Israels Central Election Commission, told The Media Line.

One reason for this cost increase is arrangements needed to hold elections during the coronavirus pandemic. Adding extra voting sites and poll workers, taking precautionary measures and dealing with the unknown are major factors driving up those costs.

The Knesset, Israels parliament, disbanded itself in late-night votes on Monday that stretched into early Tuesday morning, once again sending the country to the polls

But economic uncertainty and instability are the real cost to Israels economy of holding new elections.

Israel is suffering from a lack of governing decisions, with not passing national budgets for 2020 and 2021 among the most major. The economic situation has been made even more difficult during the past year for the country, and the entire world, due to the coronavirus pandemic.

Clearly, under normal conditions, Israel as an advanced economy with 14% unemployment and in a recession due to the pandemic should have a well-functioning government with a well-defined budget and a set of reforms. Unfortunately, we are not there, Leo Leiderman, professor of comparative economics at Tel Aviv University, told The Media Line.

I think clearly that going to the fourth elections in two years is not something to be applauded by anyone. On the other hand, we have to realize that the existing government has not been performing. It is in paralysis in its decision-making processes, said Leiderman, who is the chief economic advisor to Bank Hapoalim, Israels largest commercial bank, and formerly served at the Bank of Israel as head of the research department and a senior director.

There is a price for everything, and a democracy requires spending money

Not having an annual national budget is a major factor in the uncertainty that Israel currently is facing.

On the cusp of the new year, the government is still running itself based on the 2019 budget, alongside certain emergency pandemic- and defense-related allocations. Because of this, government ministries cannot prepare for 2021.

We dont know what to do. We dont know whether to prepare cuts in our budget or not. We are in a period of uncertainty, said a source in one ministry who asked not to be named.

The finance ministry told The Media Line on Wednesday that it will provide instructions to the ministries in the coming days.

Only after the election and the formation of a new government can a budget be planned, passed and implemented.

In perspective, 2021 seems like it will be a very challenging year for the political system and we need to have a budget as early as possible, by mid-year or later, Gil Bufman, chief economist for Bank Leumi, Israels oldest banking corporation, told The Media Line.

Government policies have longer-term impact, especially regarding structural changes in the economy, for instance with tax breaks or with policies directly connected to the countrys social fabric, Bufman said.

Wake up to the Trusted Mideast News source Mideast Daily News Email

Health care, mental health, social services and education are some of what Bufman termed, soft infrastructure. These are areas that are suffering greatly from a lack of investment by the state, he said.

A budget framework with multi-year elements of planning gives more time for longer projects like hard infrastructure projects, for instance, energy, water and transportation. We already see a lot of these in much deeper progress, such as the Tel Aviv subway system, Bufman explained.

For Bufman, the lack of a budget, and even more so during another election period, is a big challenge. We need structural change. Putting things off from year to year is not healthy, he said.

There is a large degree of inequality of what is in the pipeline. I have a feeling that the soft infrastructure projects will suffer, he said.

If and when we get the coronavirus pandemic under control and the economy starts to recover next year, our economic pace will be much lower than our potential. We could be doing much better with a stable government, infrastructure projects and reform. It is not a catastrophe, but it is a pity, it is too bad

The Alyn Hospital Pediatric & Adolescent Rehabilitation Center says its projects will suffer, too.

There is no preventative medicine. We [the healthcare sector] are dealing with emergencies because of the lack of strategic planning and policies. The government is not looking at long-term health processes, said Dr. Maurit Beeri, Alyn Hospitals director-general.

There is a lack of policy building. The HMOs are looking at things quarterly, short-term instead of long-term. Frankly, they should be investing in these young people, rather than paying far more for services when these children grow older, Beeri told The Media Line.

Yet, even with the pandemic hanging over a new governments policies, Israel is in a comparatively good position relative to other developed economies.

This is a result of the country starting the pandemic in a better position due to the growing high-technology sector and steady population growth, which much of the developed world lacks, Bufman said.

Israel has a good economy, Bufman said. We are in better shape than Spain, France and the UK. We are doing much better, he said.

Leiderman said that Israels good economy could be better if the country was in a good political situation.

If and when we get the coronavirus pandemic under control and the economy starts to recover next year, our economic pace will be much lower than our potential. We could be doing much better with a stable government, infrastructure projects and reform. It is not a catastrophe, but it is a pity, it is too bad, he said.

Still, Leiderman noted, the sooner elections occur, the sooner the political situation can become clarified which can lead to better times.

Read the rest here:
Israel Paying Economic Price for 4th Election in 2 Years - The Media Line

Read More...

Nurses Reflect on Being at the Frontline of the Coronavirus Pandemic – Mpls.St.Paul Magazine

December 28th, 2020 12:52 pm

Editors note:The nurses interviewed in this feature are former recipients of the Mpls.St.Paul Magazine Outstanding Nurses Award. We are grateful for their time and input for this feature.We are in the process of outlining our approach to this annual editorial initiative. Please send an email tooutstandingnurses@mspmag.comto let us know you would like to receive details once we are ready to move forward.

Time is of the essence when you find yourself in an emergency situation.

Just ask Kathleen Koivisto, an in-flight emergency medicine nurse with Life Link III. She doesnt waste any time when the helicopter carrying her and her team lands at the scene of an accident.

She quickly gathers all the needed suppliessuch as airway bags, a ventilator, sometimes an ultrasound, and protective gear to help keep patients safeto prepare or intubate a patient before putting them in the helicopter for the ride of their life to a level-one trauma center. But now with COVID-19, theres an extra, critical step. Before Koivisto can interface with first responders for the handoff of the patient, she must also put on all the necessary high-level personal protective equipment (PPE) to ensure she keeps herself and those around her healthy and safe. We wear masks, gloves, and eye protection with all patients. With suspicion for COVID or COVID-positive patients, we add Tiger masks or N95 and gowns. It all depends on what symptoms the patient presents.

Taking the time to put on the added PPE can be tense when a patient needs immediate attention. If youre watching a monitor and their vital signs are junky . . . it feels long, Koivisto says. A couple minutes is a long time in an emergency. Nobody has suffered because of this vital extra step, except maybe Koivistos nerves.

Not all of her patients are accident victims. Some need transport from rural hospitals to major medical centers for specialized neuro, cardiology, and trauma care. Still, COVID protocols are essential. Patients who dont require a breathing tube but are COVID positive can be transported with a Sea-Long Helmet. This allows us to give them oxygen and support their breathing without exposing the transport staff and others to the virus.

Our pandemic-filled world is testing nursesfrom administrators and educators to those on the frontlines in ways they never could have imagined when this year started. And thats saying a lot, since some of them have been doing their jobs for decades.

We talked to seven nurses who shed light on their lives and their profession during these unprecedented times.

Kristin Lau, a public health nurse in Ramsey County, works with first-time mothers, and an important part of her care strategy is visiting them in their homes. She makes house calls from the time theyre pregnant until their child is 2 years old to ensure everyone stays healthy and progresses as they should. However, since March, shes needed to turn these visits into virtual ones.

Now, instead of hopping into her car and listening to some relaxing music to clear her head between home vis- its, Lau engages with her mamas, as she affectionately refers to them, on Zoom, Microsoft Teams, and Google platforms. A day of several back-to-back virtual visits can leave her feeling extra tired. Theres a study that says it takes a lot more energy to engage over Zoom for one hour than it does in person, Lau says. I think its something like it takes three times the energy.

However, shes thankful to have the technology so she can stay engaged with the women she cares for and get a chance to still see them moving about their lives at home. Lau is always on the lookoutmonitoring her pregnant mamas for any visible signs of distress. For example, one client who was 37 weeks pregnant showed signs of preeclampsia, a life-threatening condition for both mother and baby. As soon as she popped up on my screen I could see her face was quite puffy, Lau recalls. After asking her client a series of questionsAre your hands swollen or tight? Do you have a headache? Hows your visionblurry, seeing spots? Any dizziness?she had the expectant mother check her blood pressure using the cuff thats provided by Ramsey County. Lau

knew this woman had to get medical help right away. She delivered the baby about six hours after she went to the hospital, Lau says.

As a nurse who does home visits, Lau has always had a unique portal into the personal lives of her new mothers, which helps her advise and care for them. And now, with Lau working from home, these new mothers are getting a glimpse into hers. Lau has five childrenages 9 to 20three of whom are doing distance learning at home. Plus, her husband, who has a preexisting health condition, also works from home. So thats five people, plus a couple of pet dogs, jammed into their home. Lau has set up a private room for her meetings, but that doesnt stop her clients from hearing her kids loudly engage with their siblings in another room and her dogs barking at the Amazon truck. I think its almost relatable to them to see me in the mother role, Lau says. It brings them joy.

We think about this cohort of students now in the academic programs. Theyll be the first nurses to be educated about this type of pandemic worldwide. Theyve studied and learned about pandemics in other countries, but its at a distance. Its not us. But now its here, and were living it, and were not doing so well either. Susan OConner-Von, associate professor, University of Minnesota School of Nursing

College campuses, such as St. Catherine University, have also taken to making virtual house callsbut in this instance on students. One evening back in March, Jocelyn Bessette Gorlin, an associate professor of pediatrics in the school of nursing, was teaching an advanced nursing health assessment class. That same night, the school announced it was closing the next day due to COVID-19. In the week or so leading up to the announcement, Gorlin had gotten a jump-start and had connected with the schools IT department to learn how to record Panopto videos, a kind used in the field of education, just in case the school transitioned to e-learning. We asked ourselves: How can we teach hands-on assessment skills remotely? she says.

After class that March evening, Gorlin, along with other faculty members and teaching assistants, formed an assembly line and filled Ziploc bags with the tools that the graduate students would need to practice their skills at home (tongue depressors, reflex hammers, pen lights, and more). When a ship is having trouble, you get on this raft and you do what you have to do, Gorlin says.

As it turns out, they learned they could do quite a lot. Within one week, students recorded their first video demonstrating health assessment skills on people with whom they were quarantined, such as their children, parents, and roommates. (One student who lived alone formed a mannequin out of old clothes that she beautifully assessed, Gorlin says.) Gorlin witnessed her students listening to their childrens heartbeats and gently assessing parents abdomens. The recorded videos gave us a glimpse into their home lives, she says.

Gorlin also used Google Meet and Sammy, a 140-pound medical mannequin from the school of nursing that wound up lying on her dining room table, to interface with students and offer feedback on how they could improve their assessment of a patient. Google Meet also came in handy when she held virtual lab sessions three times a week from her home. Gorlin enjoyed demonstrating how to do cranial nerve and musculoskeletal assessments on her roommateher husband, a hematologistwhod sometimes provide comic relief by swing dancing instead of sitting quietly for his checkup.

In the fall, Gorlins students returned to campus for classes on a part-time basis. While Panopto videos and Google Meet were part of the syllabus, so were small face-to-face lab classes that alternated with synchronous virtual sessions connected via technology and teamwork. At the start of class, students get their temperature taken and don gloves, masks, and face shields before meet- ing up with their assigned partner, whos wearing a plastic three-by-four-inch name tag with their picture on itas all of the PPE makes the faculty and students unrecognizable.

The teamwork Gorlin witnesses, along with the use of technology, seems a little NASA-like to her, as students depend on each other to maintain health and safety while also promoting new state-of-the-art technology that will benefit people and health care. Were in different spaces, we have high-tech technology, and were connecting remotely. Even though its estimated that this sort of hybrid teaching model takes educators about one and a half times longer to prepare and to teach, its worth it. Were preparing them to be on the frontlines, Gorlin says. So were on the frontlines to put them on the frontlines.

As of press time, in Minnesota alone, 157,096 people have tested positive for COVID-19, and 15,022 have been health care workers.* Given the state of the world, some educators thought that enrollment in nursing programs would decrease. However, enrollment in the nursing program at the University of Minnesota School of Nursing has remained steady and increased in some cases. Ive always been impressed with students, but especially now with their deep desire to become nurses in the midst of a pandemic, says Susan OConner-Von, a full-time faculty member at the University of Minnesota School of Nursing, whos been in the profession for more than 40 years. I think we were nervous. Will anyone come back, you know? Who would want to become a nurse during this time? Im just so impressed with their motivation, with their dedication, with their desire to help others.

OConner-Von and her colleagues have discussed the unanticipated experience nursing students are having right now. We think about this cohort of students now in the academic programs. Theyll be the first nurses to be educated about this type of pandemic worldwide, she says. Theyve studied and learned about pandemics in other countries, but its at a distance. Its not us. But now its here, and were living it, and were not doing so well either. This cohort of students are going to be so uniquely prepared because they have the lived experience.

During the early months of the pandemic and the social unrest that soon followed, when many of Gorlins students expressed their concerns about what was happening all around them, she set aside time when they could connect with her one-on-one. Id say 80 percent of our conversation focused on them questioning what was right in their career going forward and how they were going to do it, she recalls. Her advice? What I kept saying to the students was, This is not the journey you expected. But youre still marching forward. Youregoing to have a different step, and youre going to have a different pace to the march, but youre still moving forward, and youre going to be more resilient because of it.

My hope is that people will recognize how devastating underlying conditions can be. A silver lining to this pandemic would be if this changed peoples perspectives on health and they made lifestyle choices that improved quality of life and improved resistance to disease. Kathleen Koivisto, in-flight emergency medicine nurse with Life Link III

Michelle Curley is the director of nursing for home health agency and infusion nursing at Pediatric Home Service, and she sees this kind of resilience and desire to help firsthand. In her area of speciality, nurses travel to families homes to administer IV therapy to children. However, because these patients are especially susceptible to illness, nurses need to be extremely careful. So when a nurse has even one symptom from the CDCs long list of potential COVID-19 symptoms and has to be quarantined until tested, another nurse will readily step in to avoid having to send the vulnerable child to an infusion center. So far, eight nurses (out of 14 nurses on the team) have had to quarantinethankfully, none of them have tested positive for the virus. Two have gone on maternity leaves during this time. This can make things extra challenging. People have hardly taken PTO because everybody is trying to cover for everybody, Curley says.

There are some treatments, such as intravenous nutrition, that nurses can teach parents to administer to their children without having to leave the safety of their homes to learn how to do it. Pre-pandemic, parents and caregivers would travel to the hospital for up to three days of instruction. After hospitals went on lockdown, nurses traveled to clients homes to teach families. Now one nurse is fully dedicated to doing this training for some treatments virtually.

Of course, young patients love to see their nurses familiar faceespecially in the comfort of their home. However, these days, it can be hard to see that friendly face when its covered in PPE. To put their young patients at ease, and to get some giggles, nurses get creative and will draw eyelashes and lips on their protective goggles and face shields.

Due to a shortage of face shields during the first month of the pandemic, Curley and her crew made some from plastic, foam, and Velcro. Today theres enough PPE for all her nursing staff, and Curley wants it to stay that way. To help manage its supply, Curleys office puts it on lockdown, allowing nurses to grab only what they think theyll need over a set amount of days.

During these past nine months, the nursing profession has proven it can pivot with how nurses deliver care to patients. And they do so remarkably well. Mari Holt, vice president of clinical operations at Allina Health Mercy Hospital-Unity Campus, says one of the biggest challenges nurses continue to face is the vital yet complex layering on of head-to-toe PPE protection when engaging with COVID-positive patients or patientswhose COVID-19 status is under investigation.

This isnt Holts first experience with a health crisis that required such a high level of protection for staff, however. Back in 2014, when the Ebola crisis hit, she was part of a front-line team that not only helped Unity pre- pare for patients but also worked with three patients who may have been impacted by the virus. But Coronavirus is far different, she says. As a facility that received patients under investigation for Ebolathat was on one unit, she says. The PPE was similar but it was one person on one unit, not 18 patients on the same unit requiring multiple staff to care and be gowned up each and every day throughout the entire shift.

The Unity Campus has different wings and depending on patient volumes, it can have patients under investigation in one wing and COVID-positive patients in another clearly delineated zone. While working in a COVID zone allows nurses to go from room to room and conserve PPE, as all of the patients on that unit are positive, Holt notes, the challenge for the nursing staff is being in the equipment all of their shift. With Ebola, staff would come out of the room and be able to remove their PPE.

When asked how her teams are managing the stress, Holt notes the emotional challenges that accompany being a frontline care worker are very real. Nurses man- aging patients in isolation help anxious families juggle care strategies and telehealth-type visits. Even at a time when patients can have compassionate care visitors, she says, many family members do not want to come and visit their loved one if they have COVID. At times, she notes, nurses are the only person holding the patients hand and spending time with the patient as they take their last breath.

Nurses as a whole also experience an insiders perspective of the health disparities among underserved populations. This fact takes a toll on nurses emotionally. Lisa Sundberg, a nurse care manager who cares for home- less vets at the VA Community Resource and Referral Center in downtown Minneapolis, sees firsthand how the pandemic has affected the homeless population. According to Sundberg, some veterans deal with feelings of isolation alreadyfeelings of being cut off from other people, a loss of relationships, employment, and financial security. Homelessness increases the stress.

When the pandemic reached Minneapolis, many of these vets, some of whom have mental health illnesses, feared for their lives. The veterans were scared to death, Sundberg says. My heart went out to them. They have nothing. Theyre like, At least people have a home to go to and isolate.

Thankfully, the center is a safe haven for those in the community offering medical triage daily for trauma and medical illness, vaccines, COVID tests, and primary care for nearly 300 veterans. Its also a place for thosein need of a warm shower, a place to do their laundry, or a bagged lunch. The staff preaches the importance of handwashing and social distancing. They provide masks for their clients, but many are already wearing one when they enter the building. Also, the center helps these folks connect to other social services nearby, such as homeless shelters like Exodus, Salvation Army Harbor Lights, and House of Charities. Recently, a homeless vet who spent time with an asymptomatic friend who tested positive for coronavirus isolated himself for 14 days in his own room at one of the shelters.

Nurses are so dedicated to their patients, OConner-Von says. They have this strong sense of duty. Back when I worked in ICUs, we would have times where wed be really busy for a week or two. Wed be working double shifts, working all weekend, picking up extra time. But then after several weeks or a month wed get a reprieve. And you could maybe take that day off. This has been going nonstop since March. And so that feeling of exhaustion must be overwhelming. Not only for the patients and families but for the health care professionals.

I think about those administrators trying to support their staff and somehow do self-care and provide emotional support in whatever way they can.

Being the natural caregivers that they are, nurses often want to extend their hand to everyoneincluding their loved oneswho may be struggling. But it can be difficult to do so when theyre stretched so thin. Oftentimes this results in feelings of guilt and putting themselves on the backburner. OConner-Von uses these insights and examples to teach her nursing students that caring for themselves is also part of the job. She gives extra credit to those who take the dog for a run, read a book they dont have to underline, or call a close family member or friend just to catch up so self care becomes a habit. You cant go in burned out and provide compassionate care, she says.

Nurses try to remain hopeful and optimistic about the future. However, many are wondering how people will fare this winter, when the flu is added to the mix. Were all a little on edge, Sundberg says.

In addition, the sheer magnitude of trying to drive home the seriousness of this disease can feel overwhelming at times. Lau educates her families about the signsand symptoms of Coronavirus and where they can get a free test. Im in public health so were trying to keep our public healthy, Lau says. So it feels like a big responsibility.

She tries not to allow the heaviness she feels at times to overwhelm her. Though she admits its easy at times to get tied up in ... your own chest and in your own stress. Thats when she reminds herself that things are going to be OK and puts something on the calendar that she can look forward to, even if its just a Friday night date at Costco with her husband.

Lau says the number-one lesson they taught in nursing school was the importance of being adaptable and flexible. Never has that proven more true than it has in 2020, a year that we will never forget. Lau likens her role to being a wartime nurse. The battlefield has changed, she says. Our battlefield is our community, our grocery store, our hospitals, our schools. Were all trying to combat this [disease] and were all in this together.

As with any warfare, tactics evolve to ensure peoples safety and care. We are all adapting to be flexible, Holt says. Communication is key as things have changed, and continue to change, as we learn more about the disease. It is challenging to keep up with the changes, which is imperative for our bedside staff.

The CDC reports those with certain underlying medical conditions have a greater chance of becoming severely ill from COVID-19. Of course, not all underlying medical conditions are manageable. However, Koivisto believes that if people become more cognizant in caring for their overall health it would give them a better chance of combatting health setbacks. My hope is that people will recognize how devastating underly- ing conditions can be, she says. Many of these can be lessened with lifestyle changes like clean eating and exercise. A silver lining to this pandemic would be if this changed peoples perspectives on health and they made lifestyle choices that improved quality of life and improved resistance to disease. It would be amazing to see more Americans use food and exercise as preventative medicine to help decrease the impact of diseases like COVID and others.

Go here to read the rest:
Nurses Reflect on Being at the Frontline of the Coronavirus Pandemic - Mpls.St.Paul Magazine

Read More...

The expanding role of genomics in preconceptional ‘personalised’ medicine – ESHRE

December 26th, 2020 1:57 pm

A well attended online Campus course staged by the SIG Reproductive Genetics heard that the expansion of sequencing analysis is poised to push forward the development of cost-effective preconception tests able to identify several underlying genetic causes of infertility

The everyday implications of preconceptional medicine have so far been largely evident in lifestyle advice conducive to successful pregnancy, but a well attended online Campus meeting staged in December suggests that genomic medicine has an increasingly important role to play. Sessions at the meeting not only covered the much debated subject of genetic risk assessment by expanded carrier screening, but explored the application of genome-wide sequencing in recurrent miscarriage, in predicting ART outcomes from parental genome analysis, and even in explaining the different responses to ovarian stimulation with gonadotrophins. Such subjects, especially expanded carrier screening, are not without their ethical problems, notably in the disclosure (or not) of secondary findings, so it was also appropriate at this meeting to hear a preview of ESHREs forthcoming recommendations on expanded carrier screening in ART.

In his opening lecture Stphane Viville, a former coordinator of ESHREs SIG Reproductive Genetics, said that known genetic and chromosomal factors account for around 20% of all infertility cases, with three additional (and relatively unknown) phenotypes now moving into active research: POI, oocyte maturation defect, and preimplantation embryonic lethality, all of which were covered at this meeting. Viville added that so far at least 21 genes have been implicated in POI and advised that genetics is now getting more and more into IVF labs and no longer confined to chromosomal aberrations or microdeletions on the Y chromosome.

Much of the content of this Campus course has been explored in detail in a recent Human Reproduction Update review, whose first author, Antonio Capalbo, is deputy of ESHREs SIG Reproductive Genetics and an organiser of this course.(1) In the review, as was repeatedly implied at this meeting, Capalbo et al note that the expansion of sequencing analysis may enable the development of cost-effective preconception tests capable of identifying underlying genetic causes of infertility, which until now have largely been defined as idiopathic.

One such step in this move towards a more positive and personalised approach to preconceptional medicine is in genetic risk assessment by expanded carrier screening, which occupied a large section of this meeting. James Goldberg, prominent in the development of ECS, said its availability now steps beyond the disparities and restrictions of ethnicity-specific screening and aims to inform couples about their risk of having children with autosomal recessive and X-linked recessive disorders and thereby to support informed decision making. Nevertheless, two of the current guidance statements on ECS cited by Goldberg both from the USA are largely based on ethnicity screening with an emphasis on cystic fibrosis and spinal muscular dystrophy. ECS, said Goldberg, represents a more equitable approach to identifying risk. Such risk assessment in both the general population and IVF couples - will allow identification of those who carry recessive mutations, and thereby provide increased reproductive autonomy to couples deemed at risk and where PGT is available for embryo selection.

However, when a publicly provided ECS programme was set up in Amsterdam offering a test panel of 50 genes (at a cost of 650 euro per test) and following the guidance of the European Society of Human Genetics, there was a relatively quiet response (20%) from the general risk population, and higher (80%) from the high risk population.(2) Nevertheless, assessment of the programme, began in 2016, appeared to raise more questions than answers, and no clear resolution of how such a programme might be best provided. Capalbo and his fellow Update reviewers concluded that ECS represents one of the most effective and advanced applications of preconception genomic medicine worldwide today and is expected to grow in application in coming years.

The preview of recommendations from ESHREs Ethics Committee was specifically about ECS ahead of ART (and not just involving gamete donors). Thus, asked Dutch bioethicist Guido de Wert, would the offer of ECS to all such applicants be proportionate, and if so, for what kinds of disorders and under what conditions? Applying the three ethicists principles of proportionality, respect for autonomy and justice, De Wert firstly noted that any possible benefits should clearly outweigh any possible harms, that ECS should still be embedded in a research framework, and that a couples access to ECS should only be on condition that they take preventive measures and apply for PGT, donor gametes, or, maybe, prenatal diagnosis.

Even the outcome of fertility treatments may well be affected by genetic mutations, and such extreme outcomes as oocyte maturation failure and embryonic developmental arrest are now investigated as a genetic cause of infertility. Indeed, Semra Kahraman from theIstanbul Memorial Hospital reported that variants in more than 2000 genes are now predicted to be involved in various infertility pathways. She described her own study in which 22 IVF patients whose repeated failure was attributed to oocyte maturation failure and embryo development arrest and who were investigated using whole exome sequencing panels. Family history analysis had also identified infertility and early menopause in the family of nine of the subjects. The analysis identified genomic variants in eight of the 22 subjects, including four genes known to be lethal at the embryonic stage.

With ovarian ageing identified as one of todays most frequent causes of infertility, John Berry, an MRC investigator from Cambridge, reported in a keynote lecture that ten years ago population studies had identified four common genetic variants associated with menopause. Today, he added, there are now more than 300 loci identified, which explain around 10% of the heritable component. Too few to be clinically useful? he asked. Again, there appeared more questions than answers, notably if POI can be explained solely by monogenic alleles and if menopausal age can indeed be predicted by genetics.

The conclusions from this meeting, as well as the increasing number of genes and variants identified, suggest that genomic assessment ahead of conception may have real clinical benefits at both the individual (in identifying genetic risks in the male and female partner) and the couple level (in allowing a specific reproductive prognosis). Information at this early stage may thus lay the basis for personalised interventions, and certainly make at-risk couples better informed of their reproductive choices.

1. Capalbo A, Poli M, Riera-Escamilla A, et al. Preconception genome medicine: current state and future perspectives to improve infertility diagnosis and reproductive and health outcomes based on individual genomic data, Hum Reprod Update 2020; doi:10.1093/humupd/dmaa044

2. Henneman L, Borry P, Chokoshvili D, et al. Responsible implementation of expanded carrier screening. Eur J Hum Genet 2016; 24: e1-e12. doi:10.1038/ejhg.2015.27

View original post here:
The expanding role of genomics in preconceptional 'personalised' medicine - ESHRE

Read More...

Digbi Health partners with West Virginia University Medicine and WVU Bariatrics Surgical Weight-Loss Program to improve postoperative weight loss…

December 26th, 2020 1:57 pm

This clinical pilot will evaluate the effectiveness of Digbi Health's obesity management digital program personalized to each bariatric surgery patient, one-year post sleeve gastrectomy, based on their lifestyle, genetic and gut microbiome risks, in further reducing weight and maintaining weight loss. Obesity is a complex metabolic disease and an ongoing epidemic, with associated inflammatory, digestive, musculoskeletal, skin morbidities, as well as a risk factor for diabetes, cardiovascular disease, COVID-19, and reduced life expectancy, which currently affects 42 percent of the adult population in the United States. Bariatric surgery is the most effective long term intervention for morbid obesity, and successful bariatric surgery outcomes depend on lifelong changes in eating patterns and social support.

Research indicates individuals' genetic and gut microbiome makeups are intrinsically linked to their metabolism and following personalized nutrition recommendations and meal plans curated to an individual's genetic and gut microbiome markers may assist with further weight loss and ongoing weight maintenance post sleeve gastrectomy.

"WVU Bariatrics is excited to partner with Digbi Health to better understand how genomic, gut microbiome and metabolomic factors can contribute to successful weight loss following bariatric surgery," said Nova Szoka MD, FACS, FASMBS, Assistant Professor at J.W. Ruby Memorial Hospital, WVU Bariatrics Surgical Weight-Loss Center and principal investigator of the study.

"Digbi Health is the first company to operationalize a genetic and gut microbiome-based prescription-grade platform for doctors and payers to deliver weight loss, digestive health, and diabetes care programs at scale," said Ranjan Sinha, CEO, and founder of Digbi Health.

"Digbi is committed to empowering people suffering from obesity and chronic inflammatory lifestyle illnesses, struggling with ineffective one-size-fits-all diets, with personalized nutrition and lifestyle support that works for them. Through this collaboration with WVU Medical, we aim to deeper explore the critical importance of personalized nutrition and its direct impact on people suffering from obesity and associated illnesses," said Sinha.

More information about J.W. Ruby Memorial Hospital, WVU Medical, and Surgical Weight-Loss Center can be found here.

About Digbi HealthDigbi Healthis a first-of-its-kind precision digital therapeutics company that offers a prescription-grade digitally enabled personalized obesity and obesity-related gut, skin disorders, hypertension, and other cardiometabolic health management programs based on an individual's gut biome, genetic risks, blood markers, and lifestyle factors. Digbi Health and members of its physician network are committed to empowering people to take control of their own health and wellness. Digbi Health is prescribed by doctors, healthcare providers, and insurance companies.

SOURCE Digbi Health

digbihealth.com

Read this article:
Digbi Health partners with West Virginia University Medicine and WVU Bariatrics Surgical Weight-Loss Program to improve postoperative weight loss...

Read More...

Audentes Therapeutics Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy (XLMTM) – BioSpace

December 26th, 2020 1:57 pm

Dec. 24, 2020 23:30 UTC

SAN FRANCISCO--(BUSINESS WIRE)-- Audentes Therapeutics, an Astellas genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold for the ASPIRO clinical trial evaluating AT132 in patients with X-linked myotubular myopathy (XLMTM). XLMTM is a serious, life-threatening neuromuscular disease characterized by extreme muscle weakness, respiratory failure, and early death.

We are grateful for the efforts of our team and investigators who have worked tirelessly to answer the FDAs questions and we now look forward to resuming this study, said Natalie Holles, President and Chief Executive Officer of Audentes. We want to again extend our deepest sympathies to patients families impacted by the events earlier this year. We are deeply committed to the continued safe development of AT132 for the families and patients living with XLMTM, a disease with no existing treatments.

The company is now working to complete all clinical and regulatory activities necessary to resume dosing and plans to have discussions at a future date with the regulators on the path forward toward global registration filings for AT132.

About X-linked Myotubular Myopathy XLMTM is a serious, life-threatening, rare neuromuscular disease that is characterized by extreme muscle weakness, respiratory failure and early death. Mortality rates are estimated to be 50 percent in the first 18 months of life. For those patients who survive past infancy, there is an estimated additional 25 percent mortality by the age of 10. XLMTM is caused by mutations in the MTM1 gene that lead to a lack or dysfunction of myotubularin, a protein that is needed for normal development, maturation and function of skeletal muscle cells. The disease affects approximately 1 in 40,000 to 50,000 newborn males.

XLMTM places a substantial burden of care on patients, families and the healthcare system, including high rates of healthcare utilization, hospitalization and surgical intervention. More than 80 percent of XLMTM patients require ventilator support, and the majority of patients require a gastrostomy tube for nutritional support. In most patients, normal developmental motor milestones are delayed or never achieved. Currently, only supportive treatment options, such as ventilator use or a feeding tube, are available.

About the ASPIRO Study ASPIRO is a two-part, multinational, randomized, open-label ascending dose trial to evaluate the safety and preliminary efficacy of AT132 in XLMTM patients less than five years of age. Primary endpoints include safety (adverse events and certain laboratory measures) and efficacy (assessments of neuromuscular and respiratory function). Secondary endpoints include the burden of disease and health-related quality-of-life, and muscle tissue histology and biomarkers.

About AT132 for the treatment of X-linked Myotubular Myopathy Audentes is developing AT132, an AAV8 vector containing a functional copy of the MTM1 gene, for the treatment of XLMTM. AT132 may provide patients with significantly improved outcomes based on the ability of AAV8 to target skeletal muscle and increase myotubularin expression in targeted tissues following a single intravenous administration. The preclinical development of AT132 was conducted in collaboration with Genethon (www.genethon.fr).

AT132 has been granted Regenerative Medicine and Advanced Therapy (RMAT), Rare Pediatric Disease, Fast Track, and Orphan Drug designations by the U.S. Food and Drug Administration (FDA), and Priority Medicines (PRIME) and Orphan Drug designations by the European Medicines Agency (EMA).

About Audentes Therapeutics, Inc. Audentes Therapeutics, an Astellas company, is developing genetic medicines with the potential to deliver transformative value for patients. Based on our innovative scientific approach and industry leading internal manufacturing capability and expertise, we have become the Astellas Center of Excellence for the newly created Genetic Regulation Focus Area. We are currently exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown, with plans to expand our focus and geographic reach under Astellas. We are based in San Francisco, with manufacturing and laboratory facilities in South San Francisco and Sanford, North Carolina.

About Astellas Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+ healthcare solutions combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en

Cautionary Notes In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on managements current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201224005205/en/

Read the original post:
Audentes Therapeutics Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy (XLMTM) - BioSpace

Read More...

Hope on Hold: Promising Hemophilia B Therapy Paused by FDA – BioSpace

December 26th, 2020 1:57 pm

Even the most promising drugs can hit a pothole in the road to U.S. Food and Drug Administration (FDA) approval, particularly when working in the complicated, evolving world of gene therapies.

After touting positive Phase III resultsat ASH (American Society of Hematologys annual meeting),uniQuregot slapped with anFDA clinical holdfor their hemophilia B treatment due to a patient developing liver cancer.

Theresearch team alerted the FDA of the development after a lesion was found during a routine one-yearfollow-up.A hepatocellular carcinoma (HCC) isexpectedto be confirmed with a full surgical resection.

However, the cancer may not be related to the gene therapy, as this particular patient was high risk for liver cancerwith a long history of hepatitis C, hepatitis B virus, findings of non-alcoholic fatty liver disease and advanced age.UniQurepointed out thatchronicinfections with hep B and C are associated with 80% of HCC cases.

Patient safety will always be our top priority, and we are working closely with the FDA and our advisors to conduct a thorough investigation into the cause of this event which we expect to be completed in early 2021, said RicardoDolmetsch, Ph.D., president of R&D atuniQure. We will investigate whether there is a relationship to treatment. At this time, we do not have adequate data to determine a possible causal relationship, especially in the context of the other known risk factors.

The hold is not expected to affect the pivotal trial results as the dosing of the patients is completed.

While several treatments areavailable for hemophilia B, doctors and patients are holding out hope for a cure that will stop the disease at its source. Thats thepotential that genetic medicine has held for this area.

UniQuresdrug, AMT-061, substantially increased production of the blood-clotting protein factor IX, thefactor missing forhemophiliaBpatients,innearly all trial participants with moderate to severe disease.

Drug developers have run into a challenge with gene therapies in patients with high levels of neutralizing antibodies. Those antibodies can disarma gene therapyby attacking its viral vector delivery systembefore it ever has the chance to help thepatient.Many gene therapy trials wont enroll patients who test positive for neutralizing antibodies.

UniQuresgene therapy is delivered by an AAV5 vehicle, whichis believed to be harder to impair than other vectors.The company enrolled 23 patients with neutralizing antibodiespresent.Only one patient did not respondto the therapy. That was one who had a large amount of theantibodies- encouraging results that at least some with neutralizing antibodies could go on the therapy.

All patients in our hemophilia B gene therapy program, including the 54 patients in HOPE-B, will continue to be monitored by their care teams while we gather additional information as rapidly as possible, noted CEO Matt Kapusta. We do not anticipate any impact to our regulatory submission timeline for the hemophilia B program as a result of this clinical hold.

Featured Jobs on BioSpace

Read more here:
Hope on Hold: Promising Hemophilia B Therapy Paused by FDA - BioSpace

Read More...

WVU Medicine Children’s Dr. Mary Louise Russell brings 30-plus years experience in the treatment of children with movement issues – WV News

December 26th, 2020 1:57 pm

MORGANTOWN, W.Va. (WV News) Dr. Mary Louise Russell is a member of the team of experts at the WVU Medicine Childrens that specializes in pediatric physical medicine and rehabilitation.

She and her colleagues treat children who have movement issues due to a wide range of causes, Russell said.

Sometimes the children only have movement problems, and sometimes the movement problems are part of a more complex picture, she said. For example, children with Down syndrome can have movement problems, and they might be behind on learning to walk. But, they might have other problems, too, like developmental delay and even some other medical difficulties, like heart defects or GI problems.

She sees children of all ages, from just nine days old to beyond age 18, Russell said.

For new patients, well go all the way to 18 years. Although, for some who have had pediatric onset of chronic conditions, well see them into at least young adulthood, say mid-20s, she said. That would usually be a person with cerebral palsy.

Cerebral palsy is among the most common diagnosis she sees, Russell said.

Cerebral palsy is a problem with how the brain works that effects how somebody moves. It can be confined to the movement control part of the brain, or there may be other problems, like seizures or developmental delay, she said.

There are a variety of treatments for patients with cerebral palsy, Russell said.

The first treatment to be used is physical and occupational therapy, she said. In the United States, there is a service called Birth to Three or Early Intervention that is a federal government-supported service administered by states for kids to get in-home therapy services.

Other treatments for cerebral palsy include braces, walkers, crutches, or wheelchairs, Russell said.

Medications can be administered to reduce tone spasticity, and orthopaedic or neurosurgery can help to reduce muscle spasticity, she said. There is a variety of possible treatments that cover a range of issues.

The COVID-19 pandemic has forced her to rely on remote visits with some patients, which isnt quite the same as seeing them in person, Russell said.

I think its better than nothing, but for what I do say for a patient with cerebral palsy I really like to be able to feel how much resistance they give me when trying to stretch their arms or their legs, she said. Thats kind of a hard thing to do from a screen.

She looks forward to being able to see all of her patients in-person again in the near future, Russell said.

A lot of families right now are reluctant to bring their children for in-person visits, and I can understand. Many of these kids are medically fragile or chronically ill, she said. We just need to wait a little while longer for their in-person visits.

Russell, who has more than 30 years of medical experience, said she has seen significant leaps in what genetics can reveal about a patients condition.

What has been the biggest help to us has been advances in genetics, she said. I can remember when we would just diagnose them and say They have low muscle tone. Now, were able to identify genetic syndromes and where parts of a chromosome may be missing or duplicated.

When she was first starting out information was much more limited, Russell said.

Having genetic information helps you with set reasonable goals, she said. You may not be able to fix the underlying problem, but you know what to expect and to plan for.

Read more:
WVU Medicine Children's Dr. Mary Louise Russell brings 30-plus years experience in the treatment of children with movement issues - WV News

Read More...

The latest on the coronavirus pandemic and vaccines: Live updates – CNN

December 26th, 2020 1:57 pm

Dozens of countries have banned travel from the UK in an effort to contain a new Covid-19 variant first reported in England.

The new mutation is being called VUI-202012/01 the first "Variant Under Investigation" in the UK in December 2020. While scientists hunt for more information about the variant, its impact is already being felt, with dozens of countriesimposing restrictions on travelers from the UK.

Here's what we know so far about the Covid-19 variant:

What is a variant and why are officials concerned about this one?A variant occurs when the genetic structure of a virus changes. All viruses mutate over time and new variants are common, including for the novel coronavirus.

Like other variants, this one carries agenetic fingerprint that makes it easy to track, and it happens to be one that is now widespread in southeast England. That alone does not necessarily mean a variant is more contagious or dangerous.

But scientists advising the UK government have estimated that this variant could be up to 70% more effective at spreading than others. Peter Horby, chair of theNew and Emerging Respiratory Virus Threats Advisory Group(NERVTAG), said Monday that experts "now have high confidence that this variant does have a transmission advantage" over other variants.

The World Health Organization said Tuesday that the changes to the variant include 14 key mutations, and that some of them "may influence the transmissibility of the virus in humans," though it added that further laboratory investigations were needed.

Where did the variant originate and how has it taken hold?The new variant is believed to have originated in southeast England, according to the WHO. Public Health England (PHE) says backwards tracing, using genetic evidence, suggests the variant first emerged in England in September. It then circulated in very low levels until mid-November.

Chris Whitty, England's chief medical officer, said Saturday the variant was responsible for 60% of new infections in London, which have nearly doubled in the last week alone.

Multiple experts have also suggested that this new variant could have been amplified because of a superspreader event, meaning the current spike in cases could also have been caused by human behavior.

Is the new variant more deadly? There is no evidence as of now to suggest that the new variant is more deadly, according to Whitty and the WHO, though it is too early to tell.

Several experts have noted that in some cases, virus mutations that increase transmissibility are accompanied by a drop in virulence and mortality rates.

"As viruses are transmitted, those that allow for increased virological 'success' can be selected for, which changes the properties of the virus over time. This typically leads to more transmission and less virulence," Martin Hibberd, professor of emerging infectious disease at the London School of Hygiene & Tropical Medicine, told the SMC.

Learn more about the UK coronavirus varianthere.

See the original post:
The latest on the coronavirus pandemic and vaccines: Live updates - CNN

Read More...

Should Pregnant and Breastfeeding Patients Get the COVID-19 Vaccine? – University of Michigan Health System News

December 26th, 2020 1:57 pm

As the COVID-19 vaccine starts rolling out across the country, pregnant or breastfeeding women may be wondering if they should get it too.

First, the unknowns: Because clinical trials didnt include pregnant patients, there is no conclusive evidence related to vaccine safety and efficacy during pregnancy.

What experts do know: Pregnant patients are at higher risk of severe disease and worse outcomes from COVID-19 than non-pregnant peers and therefore would benefit from protection from the virus.

We have been following the research and federal guidance closely about pregnancy and the COVID-19 vaccine, says Molly Stout, M.D., MSCI, maternal fetal medicine director at Michigan Medicine Von Voigtlander Womens Hospital.

Based on the current information available and known risks of COVID-19 severity in pregnancy, we strongly recommend that pregnant and nursing people have access to the vaccine. We advise patients to discuss potential benefits and unknown risks specific to their individual situation with their healthcare provider.

Stout responds to some of the top questions about the COVID-19 vaccine and pregnancy:

MORE FROM MICHIGAN: Sign up for our weekly newsletter

Stout: No, the vaccines have not been studied in pregnancy specifically. A few unexpected pregnancies occurred during the vaccine trials in participants, but we dont have further data on those cases at this time. There are ongoing efforts to include pregnant women in current COVID-19 vaccine trials.

Stout: Because pregnant women were not included in the early studies, we cannot be certain of how well the vaccine will work in pregnancy. The vaccine appears to be 95% effective in reducing COVID-19 disease in non-pregnant individuals. We also do not have specific safety information in pregnancy. However, the consensus of scientists, doctors, and professional organizations in the U.S. is to support pregnant women receiving the vaccine because the health risks of COVID-19 in pregnancy can be severe.

This recommendation is based on the known risk of COVID-19 in pregnancy and the biology of mRNA vaccines which are made with a string of the virus genetic material (a message of RNA that generates protein) and not the virus itself.

The technology of mRNA vaccines has been available for a long time and in general the risks from this form of vaccine are low. Also, the safety profile of the vaccine from the randomized control trials in non-pregnant individuals suggested no significant safety concerns.

Stout: Its important to understand that there is no way to get COVID-19 from the vaccine. While some vaccines are called live because they contain the virus, the COVID-19 vaccine is not one of them. However, when your immune system is doing its job reacting to the vaccine, you may experience some flu-like symptoms.

Eighty-four percent of people in the studies experienced redness or soreness at the site of the injection, over half felt fatigue and a headache, 1/3 had muscle pain and chills and 15-20% had joint pain or a fever.

Scientists think these symptoms are related to the vaccine activating your immune system to make the cells and proteins against COVID-19. There havent been any dangerous safety events that occurred more commonly in people who got the vaccine.

Stout: Vaccination is recommended for nursing mothers because benefits of the vaccine outweigh the theoretical risks regarding the safety of vaccinating.

Vaccine trials excluded lactating individuals, so we dont have any clinical data on the safety of the vaccine during lactation. However, because of the biology of the vaccine, (which doesnt involve a live virus) there should be no transfer into breastmilk.

In fact, antibodies from the lactating mother that transfer into the breastmilk may actually protect the breastfeeding child. The Academy of Breastfeeding Medicine does not recommend stopping breastfeeding for people who get the COVID-19 vaccine.

Stout: We have seen some misinformation about this topic. It is too early to know whether the vaccine has any impact on fertility, but we dont suspect it does.

The mRNA vaccines do not incorporate into the genetic material of the individual. The mRNA is the code or message to make a protein that helps the body react more quickly if exposed to COVID-19. Thus, there is no genetic reason an egg or a sperm would be affected by the vaccine.

A pregnancy test prior to vaccination isnt recommended or required.

Stout: Because of their higher risk of exposure, certain groups have been prioritized for initial vaccine distribution, including healthcare workers, first responders and workers in long-term healthcare facilities.

The general guidance is that pregnant patients who are in these frontline categories should be able to receive the vaccine as soon as they meet the criteria and its available to them.

Stout: Right now there havent been any recommendations to change dosing or schedules for the COVID-19 vaccine for people with allergies who experience anaphylaxis.

Stout: Recent studies have suggested that pregnant people who contract COVID-19 have a higher risk of severe illness and outcomes, such as being admitted to intensive care, being put on a ventilator and dying than non-pregnant women with the virus. These risks are higher for women of color, including African-American and Hispanic populations.

Adverse pregnancy outcomes such as preterm birth for COVID-positive patients have also been reported, but data in this area are still evolving.

Given these risks, pregnant patients should consider getting vaccinated against the virus and also take all other precautions to protect themselves from exposure by socially distancing, wearing masks and following safety guidelines.

Stout: Studies are limited in this area as well. There have been cases of newborns testing positive for COVID-19 shortly after birth. Whats unclear is whether they were infected with the virus before, during, or after birth from close contact with someone who had the virus.

Most newborns who tested positive for COVID-19 had mild or no symptoms.

Stout: The vaccine has been shown to decrease your chance of having COVID-19 symptoms and severe disease. What is unknown is whether vaccinated people can still carry and transmit the virus. For this reason, the recommendation is to continue to wear masks, socially distance and maintain other recommended safety measures even for people who have been vaccinated.

Stout: There have been efforts to collect outcomes data on pregnant women who have received the vaccine and our hope is that vaccine manufacturers report this information as it becomes available.

Development of the COVID-19 vaccine is a major scientific feat and marks the fastest vaccine development and distribution to date. Doctors and scientists agree COVID-19 vaccines will be a critical measure in slowing the spread and mortality associated with COVID-19. The downside of this remarkable scientific success is we have to be able to continue to collect longer term data as we follow pregnant and non-pregnant patients forward in time and continue to track vaccine success.

Stout: Based on what we know about how COVID-19 may negatively impact a pregnant patients health, we see great benefits to patients being protected from the virus through all measures available, including the vaccine.

We expect recommendations to continue to evolve as more data are collected about these vaccines and their use in specific populations, including pregnant patients. We will be following this evolving data closely and keeping all obstetric care providers at Michigan up to date.

Like Podcasts? Add the Michigan Medicine News Break oniTunes or anywhere you listen to podcasts.

More here:
Should Pregnant and Breastfeeding Patients Get the COVID-19 Vaccine? - University of Michigan Health System News

Read More...

Covid virus will stay with us for next 10 years: BioNTech CEO – ETHealthworld.com

December 26th, 2020 1:57 pm

As the world grapples with the pandemic amid the origin of newer and potentially lethal strains, BioNTech CEO Ugur Sahin has said that the deadly virus is going to stay with us for the next decade at least.

In a virtual press conference this week, Sahin spoke about the potential virus deadline when asked when life could return to normal.

"We need a new definition of normal. The virus will stay with us for the next 10 years," he told mediapersons.

Sahin also said that the vaccine can be adjusted for the new UK variant in about six weeks.

"In principle, the beauty of the messenger technology is that we can directly start to engineer a vaccine which completely mimics this new mutation - we could be able to provide a new vaccine technically within six weeks," he was quoted as saying in media reports.

Sahin said he was confident that the new variant of the Covid-19 strain in the UK would not impact the efficacy of the vaccine.

The new strain of Covid is causing worry all around the world including in India, and it remains to be seen what effect it could have.

After the discovery of a second new variant of the novel coronavirus in Britain, the UK has reported the highest number of Covid-19 fatalities this week, since late April.

Health Secretary Matt Hancock said that the second new variant was reportedly related to travellers from South Africa, and two cases have been reported so far.

"This new variant is highly concerning because it is yet more transmissible and it appears to have mutated further than the new variant that has been discovered in the UK," he said this week.

As a result, Johnson imposed Tier Four restrictions om London and other parts of England.

View original post here:
Covid virus will stay with us for next 10 years: BioNTech CEO - ETHealthworld.com

Read More...

Collaboration to chart AI-generated map of the immune system – OutSourcing-Pharma.com

December 26th, 2020 1:56 pm

Immunai, a company specializing in comprehensive mapping of the human immune system, is joining forces with 10x Genomics. The latter will leverage its single-cell technologies to map hundreds of cell types and states. By applying its artificial intelligence (AI) and machine learning (ML) algorithms, Immunai supports biomarker discovery and insight generation to help power new therapeutic discoveries and accelerate drug development.

Outsourcing-Pharma (OSP) discussed the partnership with Luis Voloch (LV), CTO and co-founder of Immunai, and how the map generated through the collaborative effort stands to benefit drug developers.

OSP: Please tell us a bit about Immunai.

LV: Immunai is comprehensively mapping the immune system to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes. Leveraging single-cell technologies to profile cells and machine learning to map incoming data to hundreds of cell types and states, Immunai supports biomarker discovery and insight generation to better detect, diagnose, and treat disease.

The immune system is an incredibly complex, distributed system that researchers have been trying to understand with limited success for years. Immunai is the first company to fully map the immune system, generating the largest proprietary database for immunology.

Were disrupting legacy companies by analyzing 10,000 times more data from each cell than they are. No one is doing exactly what were doing.

OSP: How did you come to partner with 10x Genomics?

LV: There is an undeniable fit between the goals and capabilities of our two companies. At Immunai, we want to use AI to identify and understand novel elements within hundreds of different cell types to inform drug development, and we have been leveraging 10xs products to do that at a granular level from the start.

Through our initial work together, we identified even more mutually beneficial applications of our technologies for pharma companies and academic institutions alike. So we most recently applied to 10xs Certified Service Provider Program to give 10xs customers access to our advanced immune profiling solutions.

OSP: What does each of you bring to the table in this partnership, and how will the collaboration work?

LV: With this collaboration, we will pair our immune cell atlas with the phenotypic clinical data that hospitals, biopharma, and biotech companies derive from 10xs technology. With Immunais end-to-end computational AI pipeline customized for single-cell methods, researchers at pharmaceutical and cell therapy companies can better understand how immune cells operate with both granularity and scale. In turn, we will help 10xs customers answer clinical and translational questions related to the immune response to therapies.

OSP: Could you please talk a bit about the evolution of AI and how drug discovery professionals have made use of it to date?

LV: An analysis published earlier this year in the Journal of the American Medical Association found that the median cost of R&D for a new drug in the years between 2009 and 2018 was $985 million. This ever-increasing cost forces pharma companies to search for innovative means to create efficiencies in drug development.

Pharma companies are catching on to what Immunai already knows: AI can maximize our ability to layer data points, uncover deep insights, and advance research.

We envision AIin conjunction with human intelligenceas the major component to understanding and curing cancer. AI will increasingly have a tremendous impact on pharma. Pharma has traditionally had to experiment by testing out different compounds in a dish or in animals.

With more biological data available, AI provides a partial alternative to this that allows us to predict (without actual experiments) the impact of compounds in different biological systems. This ability has increased the speed in which we can profile and improve compounds.

OSP: What is particularly novel and noteworthy about this projectwhat do you hope to accomplish that hasnt been accomplished before?

LV: Until now, no one has been able to uncover the complexities of the immune system in the way that Immunai has. Current single-cell approaches generally operate at the scale of small academic studies because they suffer from the problem of batch effects, where noise from variation in biological samples quickly washes out any real biological signal as scale grows.

Immunais end-to-end platform is designed to manage batch effects through both proprietary lab methods and advanced AI, allowing us to build a large multi-omic single-cell database that we pair with clinical context. We train our proprietary neural network models on this data to surface insights about immune responses and facilitate the development of better therapies.

This lack of understanding of the immune system contributes to inefficiencies in drug R&D. Developing immunotherapies based on information provided by only two cells doesnt give researchers a view of the entire picture.

We believe that this collaboration will help to drastically improve the development of therapies and answer some of the biggest questions about cancer.

OSP: Is there anything youd like to add that we didnt touch upon?

LV: Our work with 10x is the second official collaboration weve announced over the past few months. In November, we announced a collaboration with Baylor College of Medicine to drive forward the development of novel NKT cell therapies. As our database continues to grow with these partnerships, we can apply learnings around immune response across different diseases from cancer to autoimmune disorders to cardiovascular diseases as well.

Follow this link:
Collaboration to chart AI-generated map of the immune system - OutSourcing-Pharma.com

Read More...

Immunity Against COVID-19 Post Recovery May Last for At Least 8 Months, Suggests New Study | The Weather Channel – Articles from The Weather Channel |…

December 26th, 2020 1:55 pm

Representative Image

As a majority of the world collectively holds its breath waiting for COVID-19 vaccinations, indirect protective measures such as social distancing and wearing of masks have been keeping people out of the coronavirus' grasp. Furthermore, the development of antibodies in individuals that have successfully beaten the virus has also served as an 'antivirus' protection for themselves and those around them.

But with that said, there has been constant speculation on just how long these antibodies and the overall immunity against COVID-19 lasts in the human system. The clouds of mystery pertaining to this particular question continue to govern scientists, virologists, and researchers. Thus far, several studies have suggested that the antibodies against the infection may wane in just a few months after recovery, thereby raising concerns of contracting the infection more than once.

Now, a team of scientists from the Monash University in Australia has given the world a Christmas gift through their new study, which has indicated that immunity against COVID-19 can last for at least eight months. The research is all the more significant at the moment, when vaccines are still in their rollout phases.

"This has been a black cloud hanging over the potential protection that could be provided by any COVID-19 vaccine, and gives real hope that once a vaccine or vaccines are developed, they will provide long-term protection," said immunologist Menno van Zelm from Monash University.

The new study specifically took into account a type of cells in our immune system known as the memory B cells or MBC. These cells function to remember any infection that the human body contracts after being invaded by a pathogen, say virus. Therefore, if an individual contracts the virus again, MBC functions to trigger a protective immune response through its memory, and thus shields an individual from re-infection.

To understand the presence of memory cells, the team chased two main components of the SARS-CoV-2 virusthe spike and the nucleocapsid proteins. The study noted that the memory B cells were rapidly generated in all the patients following the infection, and remained detectable after 240 days. This very extended presence of the memory cells showcases a long-term immune response to COVID-19. It also highlights the fact that a patients immune system has the ability to fight when re-exposed to the pathogen by the rapid production of antibodies.

"These results are important because they show, definitively, that patients infected with the COVID-19 virus do in fact retain immunity against the virus and the disease," said Dr van Zelm.

Representative Image

Interestingly, the study also ascertained that even after months of virus spread, during which millions of positive infections have been found, there have not been many reported cases of re-infections among the population across the globe.

A similar study was recently published in the journal Emerging Infectious Diseases, which also confirmed the presence of antibodies against SARS-CoV-2 after 8 months of infection in most asymptomatic or mildly symptomatic patients. The study was conducted using the immunoassays test on 58 positive patients.

When attacked by a pathogen, our immune system produces proteins called antibodies in order to fight the infection. If the infected person can produce sufficient antibodies, he can recover from the disease caused by that pathogen.

To examine how long these antibodies last in case of COVID-19, researchers monitored about 25 people diagnosed with different severities of the disease, and then collected post-infection blood samples from themstarting from day 4 to day 242 after recovery. On the other hand, they also obtained data from 36 healthy control patients between March to September, so as to compare each patient's antibody presence and levels of virus-specific immune cells.

After examining this long period data, the researchers noted that the antibodies against COVID-19especially immunoglobulin (IgG), which is the most common antibody in the human bodystarted to fade in just 20 days post-infection, just like the previous studies had suggested.

Earlier, a similar research conducted by the Chongqing Medical University in China had also suggested that people who have recovered from COVID-19 showcased a sharp decline of up to 90% in their Immunoglobulin (IgG) antibodies within the time frame of 2-3 months.

The new research is a collaborative work between Monash University, The Alfred Hospital, and the Burnet Institute in Melbourne. The study was published in the journal Science Immunology on December 22, and can be accessed here.

**

For weather, science, and COVID-19 updates on the go, download The Weather Channel App (on Android and iOS store). It's free!

See the original post:
Immunity Against COVID-19 Post Recovery May Last for At Least 8 Months, Suggests New Study | The Weather Channel - Articles from The Weather Channel |...

Read More...

Page 241«..1020..240241242243..250260..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick